Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential

admin 4 years ago No Comments

This post was originally published on this site

In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.

Prev Article Next Article

Commodities Corner: Why Basel III regulations are poised to shake up the gold market

admin June 24, 2021

London Markets: Oil and banks weigh on FTSE 100, which heads for a solid August gain

admin August 31, 2021

British Prime Minister Boris Johnson tests positive for coronavirus. What happens now?

admin March 27, 2020

Europe Markets: European stocks struggle amid earnings deluge, but banks and oil companies rise

admin April 29, 2020

The Tell: Stock-market expert sees a ‘monstrous’ rally taking hold next week, if one recent trend holds

admin August 7, 2020

Economic Report: Existing-home sales dip in January as tight supplies limit opportunities for buyers

admin February 21, 2020

About The Author

admin

Add Comment

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Market Profit Center newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin

Add Comment